Michael Waters, MD, PhD, is director of the Neurovascular Division and Stroke Program and a professor in the Department of Neurology at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix. He is board certified in neurology by the American Board of Psychiatry and Neurology with subspecialty board certification in vascular neurology.
Dr. Waters’ expertise includes stroke and neurovascular disease, including signs, symptoms, diagnostics, and treatments. He is a fellow of both the American Academy of Neurology and American Heart Association and a member of the American Neurological Association, American Society of Human Genetics, and the Society of Vascular and Interventional Neurology.
Dr. Waters received his masters in genetics from Penn State University in State College, Pennsylvania, and his doctorate in biochemistry and molecular biology from The University of Florida College of Medicine in Gainesville, where he also completed his MD. He completed his residency training at the University of California – Los Angeles Department of Neurology and completed his fellowship in clinical and molecular neurogenetics at Cedars Sinai Medical Center in Los Angeles.
Dr. Waters’ research studies include genetic mechanisms of stroke, neuroprotection in stroke, multiple clinical trials investigating stroke treatments, and neurogenetic mechanisms of neuroplasticity.
For more information or to request an appointment, please call (602) 406-6262.
Fax: (602) 406-6261
- Fellowship, Cedars Sinai Medical Center, Clinical and Molecular Neurogenetics, 2004-2005
- Residency, UCLA, Department of Neurology, 2001-2004
- Internship, University of Florida College of Medicine, 2000-2001
- MD, University of Florida College of Medicine, 2000
- PhD, University of Florida College of Medicine, Biochemistry and Molecular Biology, 1999
- MS, Pennsylvania State University, Genetics, 1989
- BS, Pennsylvania State University, 1985
- American Academy of Neurology (AAN)
- AAN Section for Neurogenetics
- AAN Section for Movement Disorders
- AAN Section for Stroke
- American Society of Human Genetics
- American Neurological Association
- Society of Vascular and Interventional Neurology
- Stroke Council, American Heart Association
- Best Doctors in America, 2011-2014
- David A. Paulus Award for Clinical Excellence, University of Florida, 2013
- Founders Award for Excellence in Translational Research, American Academy of Neurology, 2006
- Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langaee TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML, 2nd, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, Johnson JA. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg. Nov 20 2015:1-6.
- O’Connor TE, Carpenter HE, Bidari S, Waters MF, Hedna VS. Role of inflammatory markers in Takayasu arteritis disease monitoring. BMC Neurol. 2014;14:62.
- Hedna VS, Kumar A, Miller B, Bidari S, Salardini A, Waters MF, Hella M, Valenstein E, Eisenschenk S. Intracranial hypotension masquerading as nonconvulsive status epilepticus: report of 3 cases. J Neurosurg. Mar 2014;120(3):624-627.
- Gallego-Iradi C, Bickford JS, Khare S, Hall A, Nick JA, Salmasinia D, Wawrowsky K, Bannykh S, Huynh DP, Rincon-Limas DE, Pulst SM, Nick HS, Fernandez-Funez P, Waters MF. KCNC3(R420H), a K(+) channel mutation causative in spinocerebellar ataxia 13 displays aberrant intracellular trafficking. Neurobiol Dis. Nov 2014;71:270-279.
- Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Jr., Lynch JR, Zaidat OO, Rumboldt Z, Cloft HJ, Stenting, Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial I. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. Jan 25 2014;383(9914):333-341.
- Bickford JS, Ali NF, Nick JA, Al-Yahia M, Beachy DE, Dore S, Nick HS, Waters MF. Endothelin-1-mediated vasoconstriction alters cerebral gene expression in iron homeostasis and eicosanoid metabolism. Brain Res. Nov 7 2014;1588:25-36.
- Titsworth WL, Abram J, Fullerton A, Hester J, Guin P, Waters MF, Mocco J. Prospective quality initiative to maximize dysphagia screening reduces hospital-acquired pneumonia prevalence in patients with stroke. Stroke. Nov 2013;44(11):3154-3160.
- Subramony SH, Advincula J, Perlman S, Rosales RL, Lee LV, Ashizawa T, Waters MF. Comprehensive phenotype of the p.Arg420his allelic form of spinocerebellar ataxia type 13. Cerebellum. Dec 2013;12(6):932-936.
- Middlebrooks JC, Nick HS, Subramony SH, Advincula J, Rosales RL, Lee LV, Ashizawa T, Waters MF. Mutation in the kv3.3 voltage-gated potassium channel causing spinocerebellar ataxia 13 disrupts sound-localization mechanisms. PLoS One. 2013;8(10):e76749.
- Crary MA, Carnaby GD, Sia I, Khanna A, Waters MF. Spontaneous swallowing frequency has potential to identify dysphagia in acute stroke. Stroke. Dec 2013;44(12):3452-3457.